首页|帕博利珠单抗治疗驱动基因阴性的非小细胞肺癌脑转移患者的效果

帕博利珠单抗治疗驱动基因阴性的非小细胞肺癌脑转移患者的效果

扫码查看
目的 探讨帕博利珠单抗治疗驱动基因阴性的非小细胞肺癌脑转移患者的效果。方法 选取140例驱动基因阴性的非小细胞肺癌脑转移患者作为研究对象,随机分为研究组与对照组,各70例。对照组患者单纯行脑部放射治疗(立体定向放射治疗/全脑放射治疗),研究组患者在脑部放射治疗的基础上联合应用帕博利珠单抗治疗。比较两组患者临床疗效、无进展生存期、总生存期及不良反应发生情况。结果 研究组患者临床疗效优于对照组,缓解率及控制率高于对照组,无进展生存期及总生存期长于对照组,食欲减退发生率低于对照组,皮疹/瘙痒、中性粒细胞减少发生率高于对照组(P<0。05)。结论 在放射治疗的基础上联合应用帕博利珠单抗治疗驱动基因阴性的非小细胞肺癌脑转移患者能够提高治疗效果,延长患者生存期,且安全性较高。
Effect of pembrolizumab for the treatment of patients with non-small cell lung cancer with brain metastasis of driver gene-negative
Objective To explore the effect of pembrolizumab for the treatment of patients with non-small cell lung cancer with brain metastasis of driver gene-negative.Methods A total of 140 patients with non-small cell lung cancer with brain metastasis of driver gene-negative were selected as the research subjects,and they were randomly divided into study group or control group,with 70 cases in each group.Patients in the control group received simple brain radiotherapy(stereotactic radiotherapy/whole brain radiotherapy),based on which the study group received combined application of pembrolizumab for treatment.The clinical efficacy,progression-free survival,total survival,and the occurrence of adverse reactions were compared between patients of the two groups.Results The study group exhibited superior clinical efficacy,higher remission rate and control rate,longer progression-free survival and total survival,lower incidence rate of anorexia,decreased incidence rates of rash/pruritus,and neutrophils as compared with the control group(P<0.05).Conclusion On the basis of radiotherapy,jointly applying pembrolizumab to the treatment of patients with non-small cell lung cancer with brain metastasis of driver gene-negative can improve therapeutic effect,prolong patients'survival,exerting relatively high safety.

Non-small cell lung cancerPembrolizumabDriver gene-negativeBrain metastasisRadiotherapySurvival

杨怡菡、王甜甜

展开 >

陕西省人民医院肿瘤内科,陕西省西安市 710068

非小细胞肺癌 帕博利珠单抗 驱动基因阴性 脑转移 放射治疗 生存期

陕西省重点研发计划项目

2021SF-306

2024

广西医学
广西壮族自治区医学情报研究所

广西医学

CSTPCD
影响因子:1.112
ISSN:0253-4304
年,卷(期):2024.46(6)
  • 8